Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Xu, Jianming; Shen, Jie; Gu, Shanzhi; Zhang, Yun; Wu, Lihua; Wu, Jian; Shao, Guoliang; Zhang, Yanqiao; Xu, Li; Yin, Tao; Liu, Jingfeng; Ren, Zhenggang; Xiong, Jianping; Mao, Xianhai; Zhang, Ling; Yang, Jiayin; Li, Le‐Qun; Chen, Xiaoming; Wang, Zhiming; Gu, Kangsheng; Chen, Xi; Pan, Zhanyu; Ma, Kuansheng; Zhou, Xinmin; Yu, Zujiang; Li, Enxiao; Yin, Guowen; Zhang, Xiao; Wang, Shuni; Wang, Quanren

doi:10.1158/1078-0432.ccr-20-2571

Public

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Published in Clinical Cancer Research • Oct 21, 2020

Authors:

Jianming Xu

Jie Shen

Shanzhi Gu

Abstract

PURPOSE: We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: This nonrandomized, open-label, multicenter, phase II study enrolled ...

Subject

Apatinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!